Radiopharmaceuticals are rapidly becoming one of the most dynamic areas of oncology drug development. By combining molecular targeting with controlled radiation delivery, these therapies introduce a ...

Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...

By incorporating these advanced models into preclinical packages for the FDA, researchers can provide a much stronger proof ...

Ace Therapeutics, a global leader in ophthalmic disease model development and preclinical research services, today announced its customized NHP GA model development platform focused on blue ...

The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates and T cell engagers, including ZW209's promise in lung cancer. Zymeworks Inc. announced the presentation of ...

For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...

HT-KIT significantly reduces tumor burden and induces cell death in preclinical GIST models by targeting KIT mutations. Rapid tumor cell death observed within 24 hours of HT-KIT treatment, with ...

Polyrizon Ltd., a biotechnology company focused on intranasal drug delivery systems, has reported promising preclinical results for its hydrogel-based Trap & Target (T&T) platform, developed in ...

The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and ...

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody ...